Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non-Current Liabilities (2017 - 2025)

Historic Other Non-Current Liabilities for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $10.6 million.

  • Aclaris Therapeutics' Other Non-Current Liabilities rose 600.0% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year increase of 600.0%. This contributed to the annual value of $8.7 million for FY2024, which is 4032.26% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Other Non-Current Liabilities stood at $10.6 million for Q3 2025, which was up 600.0% from $10.5 million recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Other Non-Current Liabilities peaked at $33.1 million during Q4 2022, and registered a low of $6.2 million during Q4 2023.
  • Over the past 5 years, Aclaris Therapeutics' median Other Non-Current Liabilities value was $23.8 million (recorded in 2022), while the average stood at $20.0 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Other Non-Current Liabilities surged by 63653.57% in 2021 and then tumbled by 8126.89% in 2023.
  • Aclaris Therapeutics' Other Non-Current Liabilities (Quarter) stood at $28.4 million in 2021, then rose by 16.55% to $33.1 million in 2022, then crashed by 81.27% to $6.2 million in 2023, then surged by 40.32% to $8.7 million in 2024, then increased by 21.84% to $10.6 million in 2025.
  • Its Other Non-Current Liabilities was $10.6 million in Q3 2025, compared to $10.5 million in Q2 2025 and $9.0 million in Q1 2025.